Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics has launched a national investor engagement series, starting with in-person briefings in Sydney on 30 April 2026 and Perth on 4 May 2026, aimed at shareholders and prospective investors. Interim Executive Chairman Sergio Duchini will update attendees on recent corporate, clinical and operational progress, including upcoming value-defining milestones for NUZ-001, followed by Q&A and networking sessions.
The company positions these events as the first in a broader program to engage the investment community in major Australian capital cities over the year. By highlighting a “defining period” marked by key clinical and corporate milestones, Neurizon is signalling an effort to deepen investor relationships and reinforce confidence in its strategic growth plans around its lead ALS candidate.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis, with a strategy to accelerate patient access while exploring broader neurodegenerative indications through international collaborations and clinical programs.
Average Trading Volume: 566,723
Technical Sentiment Signal: Sell
Current Market Cap: A$58.84M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.